Health ❯ Diabetes ❯ Type 2 Diabetes

Medications

GLP-1 Receptor Agonists Semaglutide Ozempic Mounjaro Tirzepatide Extensior FDA Approval Ozempic and Mounjaro Orforglipron Sémaglutide

Lilly Urges Recall After Finding New Impurity in Compounded Tirzepatide With B12

The warning focuses on mass-marketed 'personalized' versions sold outside FDA review.

Brazil Nears Semaglutide Patent Expiry as Anvisa Reviews 14 Filings and Novo Nordisk Counters

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

NHS Starts Targeted Mounjaro Prescribing as Norfolk–Waveney ICB Estimates Over 11,000 Eligible

Lupin Strikes Semaglutide Licensing Deal With Galenicum Covering 23 Countries

Oxford Review Finds Rapid Weight Regain After Stopping GLP-1 Drugs

Lilly’s Triple-Agonist Retatrutide Shows Major Phase 3 Weight Loss as Grey-Market Use Prompts Warning

Argentina Launches Lilly’s Mounjaro for Obesity and Diabetes After ANMAT Approval

GLP-1 Drugs Linked to Lower Five-Year Death Risk in Colon Cancer, UCSD Study Finds

Novo Nordisk Taps Eurofarma to Launch Two Weekly Semaglutide Brands in Brazil

Resalis’ miR-22 Antisense Shows Durable Fat Loss in Animals as Phase 1 Trial Continues

Orforglipron Pill Cuts Weight 11–12% in Pivotal Phase 3 Trial

GLP-1 Drugs Linked to Lower Overall Cancer Risk in JAMA Oncology Analysis

Eli Lilly to Seek Approval of Orforglipron After Promising Phase 3 Results

UK Clinicians and Patients Refine Best Practices for GLP-1 Weight-Loss Jabs

NHS Expands Mounjaro Rollout as Regulators Flag Safety Concerns

UK Government Proposes Pharmacy Access for Weight-Loss Jabs Amid Rising Demand

Study Investigates Vision Loss in Patients Using Popular Diabetes and Weight Loss Drugs

Weight-Loss Injections Linked to Increased Fertility and 'Ozempic Babies'

Amgen's Weight-Loss Drug Shows Promise but Faces Investor Skepticism